We use cookies for a better user experience. Read our Privacy Policy

I Agree

Anticoagulants Market

Anticoagulants Market (Drug Class: Factor XA Inhibitors [NOAC/DOAC], Heparins, and Direct Thrombin inhibitors, and Vitamin K Antagonists) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Anticoagulants Market Outlook 2031

  • The global anticoagulants market was valued at US$ 30.7 Bn in 2021
  • The global market is projected to grow at a CAGR of 6.2% from 2022 to 2031
  • The global anticoagulants market is anticipated to reach more than US$ 56.6 Bn by the end of 2031

Analysts’ Viewpoint on Anticoagulants Market Scenario

Increase in cases of coagulation disorders across the globe is driving the global anticoagulants market. Surge in thrombotic complications in patients affected by COVID-19 is also augmenting the global anticoagulants market. Strategic alliances among leading companies is expected to increase product penetration, which in turn is likely to drive the global anticoagulants market growth in the next few years. Surge in geriatric population, rise in prevalence of obesity, and increase in hip & knee surgeries are also projected to fuel the global anticoagulants market during the forecast period. Governments and private players are focusing on commercializing anticoagulant products. Furthermore, manufacturers of anticoagulants are focusing on expanding their presence in developing countries such as India, China, South Africa, Brazil, and Mexico in order to increase business operations and explore new markets.

Anticoagulants Market

Anticoagulants Market Introduction

Medicines called anticoagulants stop the blood from clotting. Blood thinners are also referred to as anticoagulants. These medicines are used in order to treat and prevent blood clots that could form in blood vessels. An artery or a vein could be obstructed by blood clots. A blocked artery prevents oxygen and blood from reaching a specific area of the body such as heart, brain, or lungs. Oral anticoagulants and injectable anticoagulants are the two major forms of anticoagulants. The coagulation pathway in the blood is different for each type. Anticoagulants can be used to treat blood clots or lower the risk in situations where they are more likely to occur. People with atrial fibrillation, deep vein thrombosis, hip or knee replacement, ischemic stroke, myocardial infraction (heart attack), and pulmonary embolism can benefit from the usage of anticoagulants.

Different types of anticoagulants available in the market are Coumadin & indandiones (also called vitamin K antagonist), factor XA inhibitors, direct thrombin inhibitors, and heparin. Warfarin, sold under brand name Coumadin, is available in the U.S. only for human use. Indandiones are primarily used for pest control, especially mice and rabbit. Heparins, such as Lipo-Hepin, are injectable anticoagulants that activate antithrombin III. In the normal coagulation system, liquemin acts at multiple locations. Antithrombin III, a heparin cofactor, and heparin can prevent thrombosis by inactivating activated factor X and preventing the conversion of prothrombin to thrombin. By inhibiting the activation of the fibrin stabilizing factor, liquemin also prevents the formation of a stable fibrin clot.

Request a sample to get extensive insights into the Anticoagulants Market

Rise in Cases of Coagulation Disorders to Drive Global Anticoagulants Market

Coagulation disorders cause the body to form too many or too few blood clots. These are usually formed due to a genetic mutation and are often treatable with medications. Coagulation disorders can cause excessive bleeding if the body is unable to form blood clots properly. In other cases, these disorders could cause the body to produce blood clots too readily and increase the risk of blocked blood vessels. Bleeding disorders such as hemophilia and von Willebrand disease are genetic disorders.

According to the Centers of Disease Control and Prevention, the rate of occurrence of von Willebrand disease (VWD) is equal in men and women, affecting up to 1% of the general population. Between 2012 and 2016, more than 14,600 men, women, and children were seen at hemophilia treatment centers for the treatment of von Willebrand disease (VWD); of these, about 2/3 were women and girls. Thus, rise in cases of coagulation disorders is expected to drive the global market during the forecast period.

Increase in Hip and Knee Surgeries to Fuel Demand for Anticoagulants

Increase in number of knee and hip replacement surgeries raises the risk of developing deep vein thrombosis (DVT). Surgeries often result in prolonged immobility, which increases the risk of deep vein thrombosis (DVT) due to decreased blood flow in the body. According to the WHO 2016 report, the number of surgical procedures performed among the elderly population has increased. Rise in number of surgeries is expected to increase the likelihood of developing thromboembolic events after surgery, thereby boosting patient demand for anticoagulant treatment.

Request a custom report on Anticoagulants Market

Prevention of Thrombin Formation Bolstering Factor XA Inhibitors Segment

In terms of drug class, the global anticoagulants market has been classified into factor XA inhibitors (NOAC/DOAC), heparins, direct thrombin inhibitors, and vitamin K antagonists. The factor XA inhibitors segment accounted for major share of the global market in 2021. Factor XA inhibitor drugs include 90% of direct factor XA. Factor XA inhibitors prevent the formation of thrombin, thereby inhibiting the formation of clots. Factor XA inhibitors have predictable anticoagulant effects and do not require routine monitoring, unlike some other blood thinners.

Major Cause of Life-threatening Disorders Boosting Atrial Fibrillation & Heart Attack Segment

Based on indication, the global anticoagulants market has been segregated into deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation & heart attack, ischemic stroke, and others. The atrial fibrillation & heart attack segment dominated the global market in terms of share in 2021. Atrial fibrillation can cause conditions such as blood clots, stroke, heart failure, overactive thyroid gland or other metabolic imbalance, and other issues, which lead to thromboembolism. Anticoagulants are used to treat these conditions.

Inhibition of Blood’s Ability to Form Clots Driving Oral Segment

In terms of route of administration, the global anticoagulants market has been bifurcated into oral and injectable. The oral segment accounted for the largest share of the global anticoagulants market in 2021. A number of direct oral anticoagulants (DOACs) have been approved by the U.S. Food & Drug Administration (FDA) since 2010. Oral anticoagulants directly inhibit the blood’s ability to form clots. Implementation of different technologies for oral drug delivery is changing the market scenario.

Surge in Usage of Minimally Invasive Procedures Propelling Hospital Pharmacies Segment

Based on distribution channel, the global anticoagulants market has been divided into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominated the global market in 2021. Surge in adoption of minimally invasive procedures for spine surgeries in hospitals & clinics is expected to drive the segment during the forecast period.

Regional Analysis of Global Anticoagulants Market

As per the global anticoagulants market analysis, North America accounted for major share of the market in 2021. The market in the region is likely to grow at a high CAGR from 2022 to 2031, due to high incidence of orthotic conditions among people over the age of 60 in the region. This is driving the demand for anticoagulant drugs among the geriatric population. Cardiovascular and kidney diseases are the most common conditions that affect the elderly. Cardiovascular complications account for 50% to 55% of hospital admissions for AFIB and heart attack. Thus, the anticoagulants market demand in the U.S. and Canada is likely to rise in the near future.

The market in Asia Pacific is projected to advance at a high CAGR from 2022 to 2031. China and Japan are expected to dominate the anticoagulants market in the region in the next few years. The patient pool in Asia Pacific is expected to rise in the near future due to the increase in awareness about and improvement in healthcare infrastructure. Health care organizations in Asia Pacific are implementing guidelines to support the usage of specific drugs for the prevention and treatment of anticoagulant disorders.

Analysis of Key Players in Global Anticoagulants Market

The global anticoagulants market is fragmented, with the presence of large number of local as well as international players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the market. Prominent players in the global anticoagulants market are Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Daiichi Sankyo Company, Sanofi, Johnson & Johnson, and Pfizer, Inc.

Key Developments in Global Anticoagulants Market

  • In June 2022, Teva UK launched a generic version of apixaban, one of the oral anticoagulants that directly inhibits the factor X-factor XA, which restricts thrombin formation and development of blood clot
  • In October 2021, Twist Bioscience, a high quality synthetic DNA provider, entered into a broad-based research collaboration with Boehringer Ingelheim International GmbH to use its proprietary antibody libraries to discover the therapeutic relationship of antibodies against multiple targets provided by Boehringer Ingelheim
  • In September 2020, Bristol Myers Squibb and Pfizer announced that the U.S. District Court upheld their composition of matter patent and formulation patent covering Eliquis Apixaban anticoagulants

Key players have been profiled in the anticoagulants market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Anticoagulants Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 30.7 Bn

Market Forecast Value in 2031

More than US$ 56.6 Bn

Growth Rate

(CAGR)

6.2%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • Factor XA Inhibitors (NOAC/DOAC)
    • Heparins
    • Direct Thrombin Inhibitors
    • Vitamin K Antagonists
  • Route of Administration
    • Oral
    • Injectable
  • Indication
    • Deep Vein Thrombosis
    • Pulmonary Embolism
    • Atrial Fibrillation & Heart Attack
    • Ischemic Stroke
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Bayer AG
  • Boehringer Ingelheim International GmbH.
  • Bristol Myers Squibb
  • Daiichi Sankyo Company
  • Sanofi
  • Johnson & Johnson
  • Pfizer, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Anticoagulants Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global anticoagulants market in 2021?

The global anticoagulants market was valued at US$ 30.7 Bn in 2021.

How big will be the global anticoagulants market in 2031?

The global anticoagulants market is projected to reach more than US$ 56.6 Bn by 2031.

What was the CAGR of the global anticoagulants market from 2017 to 2021?

The global anticoagulants market advanced at a CAGR of 10.9% from 2017 to 2021.

What will be the CAGR of the global anticoagulants market during the forecast period (2022–2031)?

The global anticoagulants market is anticipated to grow at a CAGR of 6.2% from 2022 to 2031.

What are the prominent trends that affect market growth?

Rise in cases of coagulation disorders and increase in hip & knee surgeries.

Which region is likely to account for major share of the global market during the forecast period?

North America is expected to account for the largest share of the global market during the forecast period.

Who are the prominent players in the global anticoagulants market?

Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Daiichi Sankyo Company, Sanofi, Johnson & Johnson, and Pfizer, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulants Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Anticoagulants Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

    5.1. Key industry events (mergers & acquisitions, product launches, partnerships, etc.)

    5.2. Overview on the Novel Oral Anticoagulants (NOACs)

    5.3. Epidemiology of the Key Diseases

    5.4. Covid-19 Pandemic Impact on the Industry

6. Global Anticoagulants Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. Factor XA Inhibitors (NOAC/DOAC)

        6.3.2. Heparins

        6.3.3. Direct Thrombin Inhibitors

        6.3.4. Vitamin K Antagonists

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Anticoagulants Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2031

        7.3.1. Oral

        7.3.2. Injectable

    7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Anticoagulants Market Analysis and Forecast, by Indication

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Indication, 2017–2031

        8.3.1. Deep Vein Thrombosis

        8.3.2. Pulmonary Embolism

        8.3.3. Atrial Fibrillation & Heart Attack

        8.3.4. Ischemic Stroke

        8.3.5. Others

    8.4. Market Attractiveness Analysis, by Indication

9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2017–2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Anticoagulants Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Region

11. North America Anticoagulants Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. Factor XA Inhibitors (NOAC/DOAC)

        11.2.2. Heparins

        11.2.3. Direct Thrombin Inhibitors

        11.2.4. Vitamin K Antagonists

    11.3. Market Value Forecast, by Route of Administration, 2017–2031

        11.3.1. Oral

        11.3.2. Injectable

    11.4. Market Value Forecast, by Indication, 2017–2031

        11.4.1. Deep Vein Thrombosis

        11.4.2. Pulmonary Embolism

        11.4.3. Atrial Fibrillation & Heart Attack

        11.4.4. Ischemic Stroke

        11.4.5. Others

    11.5. Market Value Forecast, by Distribution Channel, 2017–2031

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. Market Value Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Drug Class

        11.7.2. By Route of Administration

        11.7.3. By Indication

        11.7.4. By Distribution Channel

        11.7.5. By Country

12. Europe Anticoagulants Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. Factor XA Inhibitors (NOAC/DOAC)

        12.2.2. Heparins

        12.2.3. Direct Thrombin Inhibitors

        12.2.4. Vitamin K Antagonists

    12.3. Market Value Forecast, by Route of Administration, 2017–2031

        12.3.1. Oral

        12.3.2. Injectable

    12.4. Market Value Forecast, by Indication, 2017–2031

        12.4.1. Deep Vein Thrombosis

        12.4.2. Pulmonary Embolism

        12.4.3. Atrial Fibrillation & Heart Attack

        12.4.4. Ischemic Stroke

        12.4.5. Others

    12.5. Market Value Forecast, by Distribution Channel, 2017–2031

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Drug Class

        12.7.2. By Route of Administration

        12.7.3. By Indication

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. Asia Pacific Anticoagulants Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. Factor XA Inhibitors (NOAC/DOAC)

        13.2.2. Heparins

        13.2.3. Direct Thrombin Inhibitors

        13.2.4. Vitamin K Antagonists

    13.3. Market Value Forecast, by Route of Administration, 2017–2031

        13.3.1. Oral

        13.3.2. Injectable

    13.4. Market Value Forecast, by Indication, 2017–2031

        13.4.1. Deep Vein Thrombosis

        13.4.2. Pulmonary Embolism

        13.4.3. Atrial Fibrillation & Heart Attack

        13.4.4. Ischemic Stroke

        13.4.5. Others

    13.5. Market Value Forecast, by Distribution Channel, 2017–2031

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Drug Class

        13.7.2. By Route of Administration

        13.7.3. By Indication

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region

14. Latin America Anticoagulants Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. Factor XA Inhibitors (NOAC/DOAC)

        14.2.2. Heparins

        14.2.3. Direct Thrombin Inhibitors

        14.2.4. Vitamin K Antagonists

    14.3. Market Value Forecast, by Route of Administration, 2017–2031

        14.3.1. Oral

        14.3.2. Injectable

    14.4. Market Value Forecast, by Indication, 2017–2031

        14.4.1. Deep Vein Thrombosis

        14.4.2. Pulmonary Embolism

        14.4.3. Atrial Fibrillation & Heart Attack

        14.4.4. Ischemic Stroke

        14.4.5. Others

    14.5. Market Value Forecast, by Distribution Channel, 2017–2031

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Drug Class

        14.7.2. By Route of Administration

        14.7.3. By Indication

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region

15. Middle East & Africa Anticoagulants Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Drug Class, 2017–2031

        15.2.1. Factor XA Inhibitors (NOAC/DOAC)

        15.2.2. Heparins

        15.2.3. Direct Thrombin Inhibitors

        15.2.4. Vitamin K Antagonists

    15.3. Market Value Forecast, by Route of Administration, 2017–2031

        15.3.1. Oral

        15.3.2. Injectable

    15.4. Market Value Forecast, by Indication, 2017–2031

        15.4.1. Deep Vein Thrombosis

        15.4.2. Pulmonary Embolism

        15.4.3. Atrial Fibrillation & Heart Attack

        15.4.4. Ischemic Stroke

        15.4.5. Others

    15.5. Market Value Forecast, by Distribution Channel, 2017–2031

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Drug Class

        15.7.2. By Route of Administration

        15.7.3. By Indication

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Market Share/Ranking Analysis, by Company, 2021

    16.3. Company Profiles

        16.3.1. Bayer AG

            16.3.1.1. Company Overview

            16.3.1.2. Product Portfolio

            16.3.1.3. SWOT Analysis

            16.3.1.4. Strategic Overview

        16.3.2. Boehringer Ingelheim International GmbH

            16.3.2.1. Company Overview

            16.3.2.2. Product Portfolio

            16.3.2.3. SWOT Analysis

            16.3.2.4. Strategic Overview

        16.3.3. Bristol Myers Squibb

            16.3.3.1. Company Overview

            16.3.3.2. Product Portfolio

            16.3.3.3. SWOT Analysis

            16.3.3.4. Strategic Overview

        16.3.4. Daiichi Sankyo Company

            16.3.4.1. Company Overview

            16.3.4.2. Product Portfolio

            16.3.4.3. SWOT Analysis

            16.3.4.4. Strategic Overview

        16.3.5. Sanofi

            16.3.5.1. Company Overview

            16.3.5.2. Product Portfolio

            16.3.5.3. SWOT Analysis

            16.3.5.4. Strategic Overview

        16.3.6. Johnson & Johnson

            16.3.6.1. Company Overview

            16.3.6.2. Product Portfolio

            16.3.6.3. SWOT Analysis

            16.3.6.4. Strategic Overview

        16.3.7. Pfizer, Inc.

            16.3.7.1. Company Overview

            16.3.7.2. Product Portfolio

            16.3.7.3. SWOT Analysis

            16.3.7.4. Strategic Overview

List of Tables

Table 01: Global Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031

Table 02: Global Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031

Table 03: Global Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031

Table 04: Global Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 05: Global Anticoagulants Market Size (US$ Bn) and Volume (Units) Forecast, by Region, 2017-2031

Table 06: North America Anticoagulants Market Value (US$ Bn) Forecast, by Country, 2017-2031

Table 07: North America Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031

Table 08: North America Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031

Table 09: North America Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031

Table 10: North America Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 11: Europe Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 12: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031

Table 13: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031

Table 14: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031

Table 15: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 16: Asia Pacific Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 17: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031

Table 18: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031

Table 19: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031

Table 20: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 21: Latin America Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031

Table 23: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031

Table 24: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031

Table 25: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 26: Middle East & Africa Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031

Table 28: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031

Table 29: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031

Table 30: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Anticoagulants Market Snapshot

Figure 02: Global Anticoagulants Market Segments With Leading Market Share (%), 2021

Figure 03: Key Industry Developments (Anticoagulants Market)

Figure 04: Global Anticoagulants Market Value (US$ Bn) Forecast, 2017‒2027

Figure 05: Global Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021

Figure 06: Global Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021

Figure 07: Global Anticoagulants Market Value Share Analysis (%), by Indication, 2021

Figure 08: Global Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021

Figure 09: Global Anticoagulants Market Value Share Analysis (%), by Region, 2021

Figure 10: Global Anticoagulants Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 11: Global Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 12: Global Anticoagulants Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 13: Global Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 14: Global Anticoagulants Market Value Share Analysis, by Indication, 2021 and 2031

Figure 15: Global Anticoagulants Market Attractiveness Analysis, by Indication, 2022–2031

Figure 16: Global Anticoagulants Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 17: Global Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 18: Global Anticoagulants Market Value Share Analysis, by Region, 2021 and 2031

Figure 19: Global Anticoagulants Market Attractiveness Analysis, by Region, 2017-2031

Figure 20: North America Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 21: North America Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031

Figure 22: North America Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 23: North America Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031

Figure 24: North America Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 25: North America Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031

Figure 26: North America Anticoagulants Market Attractiveness Analysis, by Indication, 2022–2031

Figure 27: North America Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021 and 2031

Figure 28: North America Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 29: North America Anticoagulants Market Value Share Analysis (%), by Country, 2021 and 2031

Figure 30: North America Anticoagulants Market Attractiveness Analysis, by Country, 2021 and 2031

Figure 31: Europe Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 32: Europe Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031

Figure 33: Europe Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 34: Europe Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031

Figure 35: Europe Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 36: Europe Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031

Figure 37: Europe Anticoagulants Market Attractiveness Analysis, by Indication, 2022–2031

Figure 38: Europe Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021 and 2031

Figure 39: Europe Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 40: Europe Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031

Figure 41: Europe Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 42: Asia Pacific Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 43: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031

Figure 44: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 45: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031

Figure 46: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 47: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031

Figure 48: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Indication, 2022–2031

Figure 49: Asia Pacific Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031

Figure 50: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 51: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031

Figure 52: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 53: Latin America Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 54: Latin America Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031

Figure 55: Latin America Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 56: Latin America Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031

Figure 57: Latin America Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 58: Latin America Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031

Figure 59: Latin America Anticoagulants Market Attractiveness Analysis, by Indication, 2022–2031

Figure 60: Latin America Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031

Figure 61: Latin America Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 62: Latin America Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031

Figure 63: Latin America Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 64: Middle East & Africa Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 65: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031

Figure 66: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 67: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031

Figure 68: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 69: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031

Figure 70: Middle East & Africa Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031

Figure 71: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 72: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031

Figure 73: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

245

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved